Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance

Xenobiotica

Volumn 39, Issue 1, 2009, Pages 57-71

  Fagerholm, U ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Absorption; Clearance; Liver extraction model; Metabolism; Permeability; Prediction

Indexed keywords

ALBUMIN; ALPRAZOLAM; ATENOLOL; BOSENTAN; CAFFEINE; DIAZEPAM; DIGOXIN; DILTIAZEM; ENALAPRILAT; ETOPOSIDE; FLUINDOSTATIN; FLUNITRAZEPAM; FUROSEMIDE; HEXOBARBITAL; LIDOCAINE; LORAZEPAM; LORCAINIDE; METOPROLOL; NALOXONE; NICARDIPINE; NIFEDIPINE; PROBENECID; SULPIRIDE; TENIDAP; TERBUTALINE; TESTOSTERONE; TOLBUTAMIDE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

ARTICLE; DISSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DIFFUSION; DRUG ISOLATION; ERYTHROCYTE; GASTROINTESTINAL TRANSIT; IN VIVO STUDY; LIVER CLEARANCE; LIVER METABOLISM; LIVER TRANSIT; MATHEMATICAL MODEL; METABOLIC CLEARANCE RATE; METHODOLOGY; MODIFIED DISPERSION MODEL;

EID: 61749103240     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802562652     Document Type: Article

References (82)

1. Alpini G, Garrick RA, Jones MJT, Nunes R, Tavoloni N. (1986). Water and nonelectrolyte permeability of isolated rat hepatocytes. American Journal of Physiology 251, C872-C882.
2. Anissimov YG, Bracken AJ, Roberts MS. (1997). Interconnected-tubes model of hepatic elimination. Journal of Theoretical Biology 188, 89-101.
3. Austin RP, Barton P, Mohmed S, Riley RJ. (2005). The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metabolism and Disposition 33, 419-425.
4. Bachmann K, Byers J, Ghosh R. (2003). Prediction of in vivo clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33, 475-483.
5. Baker M, Parton T. (2007). Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica 37, 1110-1134.
6. Bass L, Keiding S. (1988). Physiologically based models and strategic experiments in hepatic pharmacology. Biochemistry and Pharmacology 37, 1425-1431.
7. Berezhkovskiy LM. (2004). Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. Journal of Pharmacology Science 93, 364-374.
8. Blom A, Scaf AHJ, Meijer DKF. (1982). Hepatic drug transport in the rat: a comparison between isolated hepatocytes, the isolated perfused liver and the liver in vivo. Biochemistry and Pharmacology 31, 1553-1565.
9. Blouin A. (1977). Morphometry of liver sinusoidal cells. In, Wisse E, Knook DL editors. Kupffer cells and other liver sinusoidal cells.
10. Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, Van Bladeren PJ, Walther B. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30, 1131-1152.
11. Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in-vitro system to microsomes for the prediction of metabolic clearance. Drug Metabolism and Disposition 35, 293-301.
12. Chandra P, Brouwer KLR. (2004). The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharmaceutical Research 21, 719-735.
13. Chou C-H, Evans AM, Fornasini G, Rowland M. (1993). Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug Metabolism and Disposition 21, 933-938.
14. Chou C-H, McLachlan AJ, Rowland M. (1995). Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. Journal of Pharmacology and Experimental Therapeutics 275, 933-940.
15. Clarke SE, Jeffrey P. (2001). Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31, 591-598.
16. Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37, 1257-1294.
17. Fagerholm U. (2007a). Prediction of human pharmacokinetics - evaluation of methods for prediction of hepatic metabolic clearance. Journal of Pharmaceutics and Pharmacology 59, 803-828.
18. Fagerholm U. (2007b). Prediction of human pharmacokinetics - evaluation of methods for prediction of volume of distribution. Journal of Pharmaceutics and Pharmacology 59, 1181-1190.
19. Fagerholm U. (2008a). The role of permeability in drug ADME/PK, interactions and toxicity - presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharmaceutical Research 25, 625-638.
20. Fagerholm U. (2008b). Prediction of human pharmacokinetics - biliary and intestinal clearance and enterohepatic circulation. Journal of Pharmaceutics and Pharmacology 60, 535-542.
21. Goodman Gilman A. (2001). In, Hardman JG, Limbird LE, Goodman Gilman A. editors. The pharmacological basis of therapeutics. New York, NY, McGraw-Hill.
22. Goresky CA, Pang KS, Schwab AJ, Barker III F, Cherry WF, Bach GG. (1992). Uptake of a protein-bound polar compound, acetaminophen sulphate, by perfused rat liver. Hepatology 16, 173-190.
23. Groothuis GM, Meijer DK. (1996). Drug traffic in the hepato-biliary system. Journal of Hepatology 24, 3-28.
24. Hervé F, Urien S, Albengre E, Duché JC, Tillement J-P. (1994). Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clinical Pharmacokinetics 26, 44-58.
25. Horie T, Mizuma T, Kasai S, Awazu S. (1988). Conformational change in plasma albumin due to interaction with isolated rat hepatocyte. American Journal of Physiology 254, G465-G470.
26. Howgate EM, Rowland Yeo, K Proctor, NJ etal. (2006). Prediction of in-vivo drug clearance from in-vitro data. I: Impact of inter-individual variability. Xenobiotica 36, 473-497.
27. Ito K, Houston JB. (2005). Prediction of human drug clearance from in-vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 22, 103-112.
28. Iwatsubo T, Hirota N, Ooie T, et al. (1996). Prediction of in-vivo drug disposition from in-vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 17, 273-310.
29. Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in-vivo drug metabolism in the human liver from in-vitro metabolism data. Pharmacology and Therapy 73, 147-171.
30. Kock K, Grube M, Jedlitschky G, et al. (2007). Expression of adenosine triphosphate-binding cassette (ABC) transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clinical Pharmacokinetics 46, 449-470.
31. Lam JL, Okochi H, Huang Y, Benet LZ. (2006). In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metabolism and Disposition 34, 1336-1344.
32. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ (2005). The hepatic sinusoid in aging and cirrhosis. Effects on hepatic substrate disposition and drug clearance. Clinical Pharmacokinetics 44(2), 187-200.
33. LeCluyse EL, Bullock PL, Parkinson A. (1996). Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Advances in Drug Delivery Reviews 22, 133-186.
34. Lee HL, Chiou WL. (1989). Erythrocytes as barriers for drug elimination in the isolated liver: II. Propranolol. Pharmaceutical Research 6, 840-843.
35. Levitt MD, Strocchi A, Levitt DG. (1992). Human jejunal unstirred layer: evidence for extremely efficient luminal stirring. American Journal of Physiology 262, G593-G596.
36. Lindstedt SL, Schaeffer PJ. (2002). Use of allometry in predicting anatomical and physiological parameters of mammals. Laboratory Animals 36, 1-19.
37. MacGregor JT, Collins JM, Sugiyama Y, et al. (2001). In-vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicology Science 29, 17-36.
38. Masimirembwa CM, Bredberg U, Andersson TB. (2003). Metabolic stability for drug discovery and development. Pharmacokinetic and biochemical challenges. Clinical Pharmacokinetics 42, 515-528.
39. McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Current Drug Metabolism 463-479.
40. McManus C. (2002). In, Right hand, left hand. Cambridge, MA, Harvard University Press.
41. Meijer DK, Van der Sluijs P (1989). Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery. Pharmaceutical Research 6, 105-118.
42. Mellick GD, Roberts MS. (1999). Structure-hepatic disposition relationships for phenolic compounds. Toxicology and Applied Pharmacology 158, 50-60.
43. Miyauchi S, Sawada Y, Iga T, Hanano M, Sugiyama Y. (1993). Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharmaceutical Research 10, 434-440.
44. Naccache P, Sha'afi RI. (1973). Patterns of nonelectrolyte permeability in human red blood cell membrane. Journal of General Physiology 62, 714-736.
45. Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in-vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27, 1350-1359.
46. Ockner RK, Weisiger RA, Gollan JL. (1983). Hepatic uptake of albumin-bound substances: albumin receptor concept. American Journal of Physiology 245, G13-G18.
47. Ott P, Bass L, Keiding S. (1997). Hepatic ICG removal in the pig depends on plasma protein and hematocrit: evidence of sinusoidal binding disequilibrium and unstirred water layer effects. Hepatology 26, 679-690.
48. Pardridge WM, Sakiyama R, Fierer G. (1983). Transport of propranolol and lidocaine through the rat blood brain barrier. Primary role of globulin-bound drug. Journal of Clinical Investigation 71, 900-908.
49. Popescu D, Movileanu L, Ion S, Flonta M-L. (2000). Hydrodynaic effects on the solute transport across endothelial pores and hepatocyte membranes. Physics in Medicine and Biology 45, N157-N165.
50. Reinoso RF, Telfer BA, Brennan BS, Rowland M. (2001). Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metabolism and Disposition 29, 453-459.
51. Rich RL, Yasmina SN, Morton TA, Myszka DG. (2001). High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. Annals of Biochemistry 296, 197-207.
52. Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 33, 1304-1311.
53. Roberts MS, Ballinger LN, Weiss M. (1998). Relative dispersions of intra-albumin transit times across rat and elasmobranch perfusied liver, and implications for intra- and inter-species scaling of hepatic clearance using microsomal data. Journal of Pharmaceutics and Pharmacology 50, 865-870.
54. Roberts MS, Donaldson JD, Rowland M. (1988). Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling of hepatic elimination. Journal of Pharmacokinetics and Biopharmaceutics 16, 41-83.
55. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation. Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 41, 751-790.
56. Roberts MS, Rowland M. (1985). Hepatic elimination-dispersion model. Journal of Pharmacology Science 74, 585-587.
57. Roberts MS, Rowland M. (1986a). A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14, 227-261.
58. Roberts MS, Rowland M. (1986b). A dispersion model of hepatic elimination: 2. Steady-state considerations - influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. Journal of Pharmacokinetics and Biopharmaceutics 14, 261-288.
59. Roberts MS, Rowland M. (1986c). A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. Journal of Pharmacokinetics and Biopharmaceutics 14, 289-308.
60. Roberts MS, Rowland M. (1986d). Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. Journal of Pharmaceutics and Pharmacology 38, 177-181.
61. Rowland M, Tozer TN. (1995). In, Rowland M, Tozer TN editors. Clinical pharmacokinetics: concepts and applications.
62. Saville BA, Gray MR, Tam YK. (1992). Models of hepatic drug elimination. Drug Metabolism Reviews 24(1), 49-88.
63. Schanker LS, Nafpliotis PA, Johnson JM. (1961). Passage of organic bases into human red cells. Journal of Pharmacology and Therapy 133, 325-331.
64. Schwab AJ, Barker III F, Goresky CA, Pang KS (1990). Transfer of enalaprilat across rat liver cell membranes is barrier limited. American Journal of Physiology 258, G461-G475.
65. Schwenk M. (1980). Transport systems of isolated hepatocytes: studies on the transport of biliary compounds. Archives of Toxicology 44, 113-126.
66. Shibata Y, Takahashi H, Chiba M, Ishii Y. (2002). Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metabolism and Disposition 30, 892-896.
67. Shibata Y, Takahashi H, Ishii Y. (2000). A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metabolism and Disposition 28, 1518-1523.
68. Soars MG, Grime K, Sproston JL, et al. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in-vivo. Drug Metabolism and Disposition 35, 859-865.
69. Sohlenius-Sternbeck A-K. (2006). Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicology In-Vitro 20, 1582-1586.
70. St-Pierre MV, Lee PI, Pang KS. (1992). A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination. Journal of Pharmacokinetics and Biopharmaceutics 20, 105-145.
71. Treiber A, Schneiter R, Häusler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabolism and Disposition 35, 1400-1407.
72. Ward KW, Smith BR. (2004a). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metabolism and Disposition 32, 612-619.
73. Ward KW, Smith BR. (2004b). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans., I. Clearance. Drug Metabolism and Disposition 32, 603-611.
74. Weibel ER, Staubli W, Gnagi HR, Hess FA. (1969). Correlated morphometric and biochemical studies on the liver cell. Morphometric model, and normal morphometric data for rat liver. Journal of Cell Biology 42, 68-91.
75. Weisiger RA. (1985). Dissociation from albumin: a potentially rate-limiting step in the clearance of substrates by the liver. Proceedings of the National Academy of Sciences, USA 82, 1563-1567.
76. Wilkinson GR, Shand DG. (1975). Commentary - a physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapy 18, 377-390.
77. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. (2004). A physiological model for the estimation of the fraction dose absorbed in humans. Journal of Medical Chemistry 47, 4022-4031.
78. Wilton JC, Matthews GM. (1996). Polarized membrane traffic in hepatocytes. Bioassays 18, 229-236.
79. Winne D. (1978). Dependence of intestinal absorption in-vivo on the unstirred layer. Naun.-Schm. Archives in Pharmacology 304, 175-181.
80. Wu C-Y, Benet LZ. (2003). Disposition of tacrolimus in isolated perfused rat liver: Influence of troleandomycin, cyclosporine, and GG918. Drug Metabolism and Disposition 31, 1292-1295.
81. Yang J, Jamei M, Yeo KR, et al. (2007). Misuse of the well-stirred model of hepatic drug clearance. Drug Metabolism and Disposition 35, 501-502.
82. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahml O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS. (2008). Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. British Journal of Clinical Pharmacology 65, 680-692.